{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:51:25Z","timestamp":1760143885343,"version":"build-2065373602"},"reference-count":15,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Maryland Department of Health\u2019s Cigarette Restitution Fund Program","award":["CH-649-CRF","P30CA134274"],"award-info":[{"award-number":["CH-649-CRF","P30CA134274"]}]},{"name":"National Cancer Institute\u2014Cancer Center Support Grant (CCSG)","award":["CH-649-CRF","P30CA134274"],"award-info":[{"award-number":["CH-649-CRF","P30CA134274"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Older adults who are diagnosed with acute lymphoblastic leukemia (ALL) and are treated with chemotherapy generally have poor outcomes. Blinatumomab is a CD19\/CD3 bispecific T-cell engager that has been approved for the treatment of B-cell ALL in the relapsed\/refractory setting or in patients with minimal residual disease (MRD) positivity. We previously reported on a small cohort of older adults with newly diagnosed Philadelphia chromosome negative B-cell ALL who were treated with blinatumomab monotherapy in the first line setting. This is a long-term follow up of those patients and their clinical courses. All five patients achieved complete remission (CR) after one cycle of blinatumomab, and three were MRD-negative. Two patients completed three cycles of blinatumomab, two patients completed four cycles of blinatumomab, and one patient completed 17 cycles of blinatumomab total. In the last four years, four of these patients had relapsed disease requiring additional therapy. Two patients are alive after 61 months and 57 months since their first cycle of blinatumomab. Two of the patients died at 10 months and one died at 20 months. Here we describe the long-term clinical courses of these patients.<\/jats:p>","DOI":"10.3390\/ph17030335","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T03:03:20Z","timestamp":1709607800000},"page":"335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Follow up of Blinatumomab in Older Patients with B-Cell Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"17","author":[{"given":"Yamini K.","family":"Kathari","sequence":"first","affiliation":[{"name":"Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-1954","authenticated-orcid":false,"given":"Max","family":"An","sequence":"additional","affiliation":[{"name":"Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-3210","authenticated-orcid":false,"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[{"name":"Departments of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA"},{"name":"Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA"},{"name":"Department of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"IJH02","DOI":"10.2217\/ijh-2017-0023","article-title":"Management of older adults with acute lymphoblastic leukemia: Challenges & current approaches","volume":"7","author":"Sawalha","year":"2018","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.beha.2017.08.001","article-title":"Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies","volume":"30","author":"Liesveld","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Valtis, Y.K., Flamand, Y., Shimony, S., Place, A.E., Silverman, L.B., Vrooman, L.M., Brunner, A.M., Sallan, S.E., Wadleigh, M., and Stone, R.M. (2024). Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia, online ahead of print.","DOI":"10.1038\/s41375-023-02115-4"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Niyongere, S., Sanchez-Petitto, G., Masur, J., Baer, M.R., Duong, V.H., and Emadi, A. (2020). Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Pharmaceuticals, 13.","DOI":"10.3390\/ph13060124"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: Results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.leukres.2008.08.025","article-title":"Combination of rituximab with blinatumomab (MT103\/MEDI-538), a T cell-engaging CD19-\/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells","volume":"33","author":"Wissing","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15330338211037434","DOI":"10.1177\/15330338211037434","article-title":"Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis","volume":"20","author":"Ponvilawan","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1280759","DOI":"10.3389\/fimmu.2023.1280759","article-title":"Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2016-11-749143","article-title":"Targeting CD19: The good, the bad, and CD81","volume":"129","author":"Velasquez","year":"2017","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:17Z","timestamp":1760105357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/3\/335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ph17030335"],"URL":"https:\/\/doi.org\/10.3390\/ph17030335","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}